



Shingles Vaccination Programme

Introduction of Shingrix® vaccine for the whole programme and expansion of eligible cohorts

From 1 September 2023, all newly eligible individuals will be offered 2 doses of the non-live shingles vaccine Shingrix® instead of Zostavax®. In addition to this, the eligibility for the severely immunosuppressed and immunocompetent cohorts will change to allow individuals to be protected at an earlier age. This is based on recommendations from the Joint Committee on Vaccination and Immunisation (JCVI)¹.

Although shingles can occur at any age, the risk and severity of shingles and its complications increases with age and is high in individuals who are severely immunosuppressed. It is important to ensure that those at greatest risk are vaccinated at an earlier age and this forms the basis of the JCVI recommendations.

1. Minutes of 06 February 2019 JCVI main meeting:
<https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/424913874479>

CONTENTS

- Timing and eligibility
- Immunocompetent patients
- Vaccine supply
- Patient Group Directions (PGDs)
- Information and guidance for healthcare practitioners
- Leaflets, posters, record card, postcard, stickers and resources
- Consent
- Reporting suspected adverse reactions
- It's time to nominate your shingles vaccine lead
- Vaccine coverage data collection
- Supporting national shingles programme resources
- Vaccines for the 2023 to 2024 children's flu programme supplied by UKHSA
- LAIv ordering information for General Practice
- Multi-Branch Practices and LAIV allocations
- LAIv ordering information for school-age providers
- Inactivated flu vaccine ordering
- ImmForm customers should report long-term changes to opening hours for deliveries
- DTaP/IPV/Hib/HepB vaccine ordering
- Change in schedule for the routine and eligible GBMSM under age 25 years
- Update to Bexsero Patient Information Leaflet
- Registering for a new or updating your existing ImmForm vaccine ordering account
- The EU FMD and Delegated Regulation as applicable to UKHSA-supplied vaccines for the national immunisation programme
- MMR vaccine ordering
- Shingrix® vaccine ordering information

Key points about the changes to the programme:

1 Change of vaccine:

- Shingrix® will replace Zostavax® for the whole shingles programme
- Shingrix® will require a 2-dose schedule for all cohorts. The dosing interval will differ for severely immunosuppressed and immunocompetent patients
- Shingrix® should be offered to all people reaching eligible age on or after 1 September 2023. Those cohorts previously eligible for Zostavax® who are under 80 years of age, should continue to be offered Zostavax® until central stocks deplete (via ImmForm), after which they should be offered Shingrix®
- individuals who have received Zostavax® as part of the national programme previously should not be revaccinated with Shingrix®
- Shingrix® can be administered alongside other vaccines. Please refer to the Shingles Green Book chapter 28a (see [weblink 1](#)) for more information
- in 2018, it was agreed that patients could be immunised with shingles vaccine at any point in the year as soon as they reach eligible age. Shingles vaccination should continue to be offered year-round

2 Changes to eligibility:

a. Severely immunosuppressed cohort:

- since September 2021, Shingrix® has been available to immunocompromised individuals aged 70 to 79 years, who are contraindicated to receive Zostavax®, as part of the NHS shingles vaccination programme
- the forthcoming change from 1 September 2023 will expand the eligibility to all immunocompromised individuals aged 50 years and over (with no upper age limit)
- immunocompromised individuals who have already received 2 doses of Shingrix® do not need re-vaccination
- immunocompromised individuals represent the highest priority for vaccination given their risk of severe disease, and therefore the programme aims to catch up all immunocompromised individuals aged 50 years and over in the first year of the programme implementation
- the second dose should be given 8 weeks to 6 months after the first dose for this cohort, in line with the Summary of Product Characteristics (SmPC) – see [weblink 2](#)




b. Immunocompetent cohort:

- the eligible age for immunocompetent individuals will change from 70 to 60 years of age for the routine cohort, in a phased implementation over a 10 year period
- the routine offer will move from 70 to 60 years of age in 2 stages over a 10 year period as follows:
 - During stage 1 (1 September 2023 to 31 August 2028):
 - Shingrix® will be offered to those turning 70 and 65 years on or after 1 September 2023
 - Zostavax® will be offered to persons aged between 70 to 79 that were eligible for the vaccination programme before 1 September 2023. Once all stocks of Zostavax® are exhausted, these individuals can be offered Shingrix® if they have not previously been given a shingles vaccine
 - During stage 2 (1 September 2028 to 31 August 2033):
 - Shingrix® will be offered to those turning 65 and 60 years of age
 - from 1 September 2033 and thereafter, Shingrix® will be offered routinely at age 60 years
 - those who have been previously eligible (ie in stages 1 and 2) will remain eligible until their 80th birthday
 - immunocompetent individuals remain eligible until their 80th birthday (as is currently the case). However, where an individual has turned 80 years of age following their first dose of Shingrix®, a second dose should be provided before the individual's 81st birthday to complete the course
 - for immunocompetent individuals the second dose can be given 6 to 12 months after the first dose

For any operational queries, please contact your NHS England Regional Public Health Commissioning Team.

For clinical queries or queries about supporting programme resources, please email immunisation@ukhsa.gov.uk.



Implementation stages	Delivery period	Eligible for first dose
Stage 1 (5 year duration)	1 Sept 2023 to 31 Aug 2028	Those who reach age 65 or 70 years during this period should be called in on/after their 65th or 70th birthday*
Stage 2 (5 year duration)	1 Sept 2028 to 31 Aug 2033	Those who reach age 60 or 65 years during this period should be called in on/after their 60th or 65th birthday*
Ongoing routine offer	1 Sept 2033 onwards	Those turning 60 years of age should be called in on/after their 60th birthday*

*those that become eligible but do not take up the vaccine offer immediately remain eligible until their 80th birthday. Individuals who were eligible for Zostavax® should continue to receive Zostavax® until central stocks deplete (via ImmForm), after which time they should receive Shingrix®. The 80th birthday upper age cut off remains in place for the immunocompetent cohort regardless of vaccine offered.

The annual shingles vaccine coverage data for the 8th year of the programme in England (financial year 2021 to 2022) shows that cumulative vaccine coverage for each birth cohort continues to increase each year. This latest data suggests recovery of the programme in 2021 to 2022 after the programme was impacted by the COVID-19 pandemic in the year prior.

Results assessing the impact of shingles vaccination in the 5 years after the introduction of the Zostavax® programme in England showed large reductions in both GP consultations and hospitalisations for herpes zoster and post-herpetic neuralgia. Therefore, it is important to continue to offer the shingles vaccine to all eligible patients, particularly in regions with lower coverage and those impacted by the COVID-19 pandemic.

We would like to take this opportunity to thank everyone involved in commissioning and operationally delivering the national NHS shingles vaccination programme.



Immunocompetent patients – timeline for the phased implementation of the change to eligible age

Implementation stages	Age attained (years) within first programme year (1 Sept 2023 to 31 Aug 2024)	Dates of birth	Programme year offered		Age offered at
Previously eligible cohorts:	70 to 79	before 1 Sept 1953	those in the cohort previously eligible for the Zostavax® programme prior to 1 Sept 2023 remain eligible for Zostavax® until stocks deplete, after which time they become eligible for Shingrix®		
Stage 1:	70	1 Sept 1953 to 31 Aug 1954	Year 1	1 Sept 2023 to 31 Aug 2024	70
	69	1 Sept 1954 to 31 Aug 1955	Year 2	1 Sept 2024 to 31 Aug 2025	70
	68	1 Sept 1955 to 31 Aug 1956	Year 3	1 Sept 2025 to 31 Aug 2026	70
	67	1 Sept 1956 to 31 Aug 1957	Year 4	1 Sept 2026 to 31 Aug 2027	70
	66	1 Sept 1957 to 31 Aug 1958	Year 5	1 Sept 2027 to 31 Aug 2028	70
Stage 2:	65	1 Sept 1958 to 31 Aug 1959	Year 1	1 Sept 2023 to 31 Aug 2024	65
	64	1 Sept 1959 to 31 Aug 1960	Year 2	1 Sept 2024 to 31 Aug 2025	65
	63	1 Sept 1960 to 31 Aug 1961	Year 3	1 Sept 2025 to 31 Aug 2026	65
	62	1 Sept 1961 to 31 Aug 1962	Year 4	1 Sept 2026 to 31 Aug 2027	65
	61	1 Sept 1962 to 31 Aug 1963	Year 5	1 Sept 2027 to 31 Aug 2028	65
	60	1 Sept 1963 to 31 Aug 1964	Year 6	1 Sept 2028 to 31 Aug 2029	65
	59	1 Sept 1964 to 31 Aug 1965	Year 7	1 Sept 2029 to 31 Aug 2030	65
	58	1 Sept 1965 to 31 Aug 1966	Year 8	1 Sept 2030 to 31 Aug 2031	65
	57	1 Sept 1966 to 31 Aug 1967	Year 9	1 Sept 2031 to 31 Aug 2032	65
	56	1 Sept 1967 to 31 Aug 1968	Year 10	1 Sept 2032 to 31 Aug 2033	65
	55	1 Sept 1968 to 31 Aug 1969	Year 6	1 Sept 2028 to 31 Aug 2029	60
	54	1 Sept 1969 to 31 Aug 1970	Year 7	1 Sept 2029 to 31 Aug 2030	60
	53	1 Sept 1970 to 31 Aug 1971	Year 8	1 Sept 2030 to 31 Aug 2031	60
	52	1 Sept 1971 to 31 Aug 1972	Year 9	1 Sept 2031 to 31 Aug 2032	60
	51	1 Sept 1972 to 31 Aug 1973	Year 10	1 Sept 2032 to 31 Aug 2033	60
Ongoing routine offer:	50 and under	on or after 1 Sept 1973	Year 11 onwards	from 1 Sept 2033 onwards	60

Vaccine supply

Shingrix® will be available to order online via the ImmForm website at [weblink 3](#). See the ImmForm helpsheet at [weblink 4](#) for information on registering for an ImmForm account. Ordering controls may be in place to enable UKHSA to balance incoming supply with demand. Details on ordering will be available on ImmForm and in Vaccine Update in due course. Please make sure that local stocks of vaccine are rotated in fridges so that wastage is minimised. It is recommended that practices hold no more than 2 weeks' worth of stock. Locally held stocks of Shingrix® ordered via ImmForm for the previous shingles immunocompromised programme can be used for eligible cohorts in the expanded programme.

Zostavax® will remain available through ImmForm until central stocks deplete. Zostavax® can continue to be offered to those cohorts previously eligible for Zostavax® who are under 80 years of age, after which time they should receive Shingrix®.

Shingrix® can be administered alongside other vaccines, which may increase opportunities to make an opportunistic offer. Unlike influenza vaccination, shingles vaccination is not seasonal and should be offered year-round. Please refer to the Shingles Green Book chapter 28a at [weblink 1](#) for more information.

Zostavax® Patient information leaflet at [weblink 5](#).

Shingrix® Patient Information leaflet (PIL) at [weblink 6](#).

Patient Group Directions (PGDs)

An updated Shingrix® PGD template will be produced by UKHSA for NHS England areas to authorise for their commissioned services. You can view this on GOV.UK PGD collection at [weblink 7](#).

Information and guidance for healthcare practitioners

Detailed clinical guidance on shingles and shingles vaccination is contained in chapter 28a of Immunisation Against Infectious Disease (the Green Book) – see [weblink 1](#).

Healthcare practitioner information and guidance to support the Shingrix® programme including e-learning and a training slide set will be available on the Shingles vaccination guidance for healthcare practitioners webpage at [weblink 8](#).

Leaflets, posters, record card, postcard, stickers and resources

Updated patient information materials will be available on the Shingles vaccination programme webpage at [weblink 9](#). To order from the Health Publications website, see [weblink 10](#).

Consent

Guidance on informed consent can be found in chapter 2 of the Green Book available at [weblink 11](#).

Reporting suspected adverse reactions

Health professionals and those vaccinated are asked to report suspected adverse reactions through the online Yellow Card scheme, by downloading the Yellow Card app or by calling the Yellow Card scheme on 0800 731 6789 9am – 5pm Monday to Friday or scan this QR code.



See [weblink 12](#)

It's time to nominate your shingles vaccine lead

You can use the shingles checklist to plan your preparation, get your resources ready, complete your online learning, and order your patient resources to really help implement this programme effectively.

Name of shingles vaccination lead: _____

This checklist has been designed to help immunisation practitioners plan their shingles immunisation programme

1 Prepare your shingles information pack and order your free resources from the Health Publications website

- bookmark the UKHSA shingles vaccination programme web page: www.gov.uk/government/collections/shingles-vaccination-programme
- Green Book chapter – shingles chapter 28a
- Patient Group Directions (PGDs) – Zostavax® PGD and Shingrix® PGD (all PGDs must be appropriately authorised before use)
- information for healthcare practitioners – shingles information document
- eligibility table poster (product code: S23PFO2) – shingles table eligibility poster
- stage 1 eligibility poster (product code: S23PO1) – shingles stage 1 eligibility poster
- eligibility poster (product code: 2942856B) – shingles eligibility poster
- leaflet (product code: C23SGX1EN) – shingles vaccination leaflet
- record card (product code: S23RC01) – shingles vaccination record card
- sticker (product code: S23ST04) – shingles vaccination stickers
- consider including shingles information on patient TV systems in waiting rooms, download the banners to use on your digital displays

2 Check your knowledge

- complete the shingles session in the vaccine preventable diseases module of the e-Learning for Health immunisation course www.e-lfh.org.uk/programmes/immunisation
- read through the latest version of Shingles vaccination guidance: information for healthcare practitioners www.gov.uk/government/publications/shingles-vaccination-guidance-for-healthcare-professionals
- share learning with all those involved in the programme, including GPs, practice nurses and reception staff booking appointments. Consider running a training and information session for colleagues using the national slide set: www.gov.uk/government/collections/shingles-vaccination-programme

Shingles infection is not related to season but it is related to age so don't let your patients wait once they become eligible. The shingles vaccine may be their best birthday present this year.

3 Plan your programme: remember shingles vaccination can be offered all year round

- inform your patient participation group of previous years vaccine uptake and focus for this year
- identify eligible patients who have not received shingles vaccine previously:
 - individuals between 70 and 80 years of age
 - from 1 September 2023 severely immunosuppressed individuals 50 years of age and above
 - from 1 September 2023 immunocompetent individuals who turn 65 and 70 years of age
 - eligible housebound patients and patients in care homes
 - undertake call/recall for patients in the immunocompetent and immunosuppressed cohorts
- ensure current in-date authorised Patient Group Directions (PGDs) are available and that a prescriber has prepared a Patient Specific Direction (PSD) if non-registered staff are administering the vaccine
- make sure immunisers have a copy of the PGDs and the Green Book Chapter 28a available to refer to when discussing vaccination with their patients and checking their medical history
- ensure eligible patients are flagged on the system to promote opportunistic vaccination (for example at chronic disease clinics, routine appointments)
- schedule appointments for patients to receive their second dose of Shingrix vaccine
- each month / quarter, update your list of patients still eligible and feedback progress made at practice meetings
- remember to add your requirement for shingles vaccine in with your childhood vaccine order through ImmForm. Aim to hold no more than 2 weeks' worth of stock
- celebrate your success



Download the above web banners at: <https://www.healthpublications.gov.uk/ViewArticle.html?spn=Shingleswebbandsocialmedia>
Product code: S23SMWB1

Remember to advise patients that having their routine shingles vaccine is a good way of looking after their health so that they can get on with enjoying life without the pain of shingles



Shingles infection is not related to season but it is related to age so don't let your patients wait once they become eligible. The shingles vaccine may be their best birthday present this year.

© Crown copyright 2023. Product code: S23CHEN, 1st SK JUL 2023 (APR). UKHSA Gateway number: 2023081. If you would like to order more copies of this poster please visit Health Publications www.healthpublications.gov.uk or call 0300 123 1022.

Product code: S23CHEN – [Weblink 13](#)

Vaccine coverage data collection

Dose 1 and dose 2 coverage of the Shingrix® vaccination will be collected. GP practice-level shingles vaccine coverage will be based on data automatically uploaded via participating GP IT suppliers to the ImmForm website (a website used by UKHSA and NHS to collect data on vaccine coverage and provide vaccine ordering facilities for the NHS) on a monthly basis for the first 12 months whereafter it will be a quarterly collection.

From September 2023 data will be collected on the following:

For the Immunocompromised cohort:

Denominator:

The number of individuals aged 50 years old and over (no upper age limit) registered at a GP practice who have a SNOMED code that indicates their immunocompromised status.

Numerator:

The number of individuals aged 50 years old and over (no upper age limit) registered at a GP practice who have a SNOMED code that indicates their immunocompromised status and have the following SNOMED codes:

- (a) 39756611000001109, 39655511000001105, 38737511000001105 or 38736811000001106 (indicating receipt of first dose of Shingrix®)
- (b) 1326111000000107 (indicating receipt of second dose of Shingrix®).

For the Immunocompetent cohort:

Denominator:

The number of individuals aged 65 to 79 years old registered at a GP practice.

Numerator:

The number of individuals aged 65 to 79 years old registered at a GP practice and have the following SNOMED codes:

- (a) 39756611000001109, 39655511000001105, 38737511000001105 or 38736811000001106 (indicating receipt of first dose of Shingrix®)
- (b) 1326111000000107 (indicating receipt of second dose of Shingrix®)

Plus

The number of individuals aged 80 years old registered at a GP practice who have the following SNOMED codes:

- (a) 39756611000001109, 39655511000001105, 38737511000001105 or 38736811000001106 (indicating receipt of first dose of Shingrix®) when aged 79
- (b) 1326111000000107 (indicating receipt of second dose of Shingrix®) when aged 80.

The existing Zostavax® vaccine coverage collection will continue for those aged 71 to 79 years of age as it is still offered to those age groups while stock deplete.

The data will be validated and analysed by UKHSA to check data completeness, identify and query any anomalous results and describe epidemiological trends.

Annual reports of shingles vaccine uptake are available on GOV.UK – see [weblink 14](#).

Supporting national shingles programme resources

Health professional guidance

Shingles vaccination: guidance for healthcare professionals at [weblink 8](#).

Shingles slide set at [weblink 15](#).



Eligibility for shingles vaccine

If you have a severely weakened immune system (as described in the Green book chapter) you will be offered the shingles vaccine from 50 years of age

If you are over 70 years of age and have not had shingles vaccine before you remain eligible up to your 80th birthday

ELIGIBLE FROM (YOUR BIRTHDAY)

CATCH UP STAGE 1
70th

CATCH UP STAGE 2
65th
60th
60th

ROUTINE
60th

DATES OF BIRTH

PROGRAMME START DATE

PROGRAMME YEAR


Immunisation
The safest way - protect yourself

© Crown copyright 2023. Product code: S23PFO2. © 04.03.2023 (NHS). UKHSA Gateway number: 20230403. If you would like to order more copies of this poster please visit Health Publications www.healthpublications.gov.uk or call 0300 123 1900

Shingles programme stage 1 and 2 landscape poster

Product code: S23PFO2

– [Weblink 16](#)



Eligibility for shingles vaccine

Aged 70-79 years?
Everyone aged between 70 and 79 years is eligible for the shingles vaccine up to 79 years of age.

If you are 65, you are also eligible for your shingles vaccine.

If you have a severely weakened immune system you will be eligible for shingles vaccine from 50 years of age.

Protect yourself from the pain of shingles – speak to your GP surgery about having your vaccine today!

Immunisation
Having your routine vaccines is important to give you the best protection.

Eligible from (YOUR BIRTHDAY)

Turning 70?
70th

Turning 65?
65th

DATES OF BIRTH

PROGRAMME START DATE

PROGRAMME YEAR

Immunisation
The safest way - protect yourself

© Crown copyright 2023. Product code: 2942856B. © 04.03.2023 (NHS). UKHSA Gateway number: 20230403. If you would like to order more copies of this poster please visit Health Publications www.healthpublications.gov.uk or call 0300 123 1900

Shingles vaccination eligibility portrait poster

Product code: 2942856B

– [Weblink 17](#)



Eligibility for shingles vaccine

If you have a severely weakened immune system (as described in the Green book chapter) you will be offered the shingles vaccine from 50 years of age

If you are over 70 years of age and have not had shingles vaccine before you remain eligible up to your 80th birthday

Eligible from (YOUR BIRTHDAY)

Turning 70?

Turning 65?

DATES OF BIRTH

PROGRAMME START DATE

PROGRAMME YEAR


Immunisation
The safest way - protect yourself

© Crown copyright 2023. Product code: S23PO1. © 04.03.2023 (NHS). UKHSA Gateway number: 20230403. If you would like to order more copies of this poster please visit Health Publications www.healthpublications.gov.uk or call 0300 123 1900

Shingles vaccination stage 1 portrait poster

Product code: S23PO1

– [Weblink 18](#)



Name of shingles vaccination lead:

This checklist has been designed to help immunisation practitioners plan their shingles immunisation programme

1 Prepare your shingles information pack and order your free resources from the Health Publications website
www.healthpublications.gov.uk
Download the UKHSA shingles vaccination programme web page
www.ukhsa.gov.uk/shingles-vaccination-programme
Download the Green book chapter 28a
Download the shingles vaccination programme P2G and Shingles P2G/PD2G PDQs must be appropriately authorised before use
Download the shingles vaccination programme shingles information document
• shingles table poster product code S23PFO2 – shingles table eligibility poster
• stage 1 eligibility poster product code S23PO1 – shingles stage 1 eligibility poster
• shingles vaccination leaflet product code S23PO1 – shingles vaccination leaflet
• leaflet product code C23301EN – shingles vaccination leaflet
• record card product code S23PO1 – shingles vaccination record card
• shingles vaccination record card
• shingles vaccination record card
• consider including shingles information on patient TV systems in waiting rooms, consider including shingles information on your digital display

2 Complete the shingles season in the vaccine preventable diseases module of the e-Learning for Health immunisation course www.e-learning-for-health.nhs.uk/programmes/immunisation
• read the shingles vaccination programme guidance for healthcare practitioners www.gov.uk/government/publications/shingles-immunisation-programme
• share learning with all those involved in the programme, including GPs, practice nurses and reception staff booking appointments. Consider running a training and information session for your practice and additional slide set www.gov.uk/government/publications/shingles-immunisation-programme

Shingles infection is not related to season but it is related to age so don't let your patients wait once they become eligible. The shingles vaccine may be their best defence present this year.

Shingles vaccination checklist

Product code: S23CHEN

– [Weblink 13](#)

Patient facing resources



Guide to shingles vaccine leaflet

Product code:
C23SGX1EN
– Weblink 19



Shingles birthday themed invitation postcard

Product code:
S23PC02
– Weblink 20



Shingles birthday reminder invitation postcard

Product code:
S23PC03
– Weblink 20



Shingles social media cards

Product code: S23SMWB1
– Weblink 23



Shingles stickers

Product code:
S23ST04
– Weblink 22



Shingles vaccination record card

Product code: S23RC01
– Weblink 21

All patient facing resources and the health professional posters can be ordered free of charge via [weblink 10](#).

All users need to register to receive deliveries. If you register as a health professional, you can order 500-1000 copies on the website. For larger quantities, please call 0300 123 1002.

Vaccine supply

Routine vaccination programme

Vaccines for the 2023 to 2024 children's flu programme supplied by UKHSA

All flu vaccines for the 2023 to 2024 children's flu programme will be available to order by NHS providers in England via UKHSA's ImmForm website.

UKHSA does not supply any flu vaccines for patients aged 18 years and over.

Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Vaccines and availability

The 2 vaccines available, indicative ordering dates and the groups these vaccines should be ordered for are shown in the table below. At present these timings remain subject to change.

The latest and most accurate information on availability of centrally supplied vaccines for the children's flu programme is available on the ImmForm news page at all times – see [weblink 24](#). It is strongly advised that all parties involved in the provision of influenza vaccines to children ensure they remain up to date with this.

Vaccine	Manufacturer	Available to order for	Anticipated order opening for all providers
Fluenz® Tetra (LAIV)	AstraZeneca	<ul style="list-style-type: none"> All children from 2 years of age to school year 11; and Children in clinical risk groups aged 2 to <18 years* 	Early September
Cell Based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc)	Seqirus	<ul style="list-style-type: none"> Children in clinical risk groups aged 6 months to <2 years All other eligible** children aged 2 to <18 years for whom LAIV is unsuitable 	Early September

*unless LAIV clinically contraindicated or otherwise unsuitable.

**Children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to <18 years.

Editing Fluenz® Tetra (LAIV) orders

Due to the anticipated large volume of orders for Fluenz® Tetra in the first few weeks of ordering, orders for this product will be assembled as soon as they are placed and will not be editable. If you need to make an adjustment to your order after it has been placed, you will need to contact helpdesk@immform.org.uk for assistance.

LAIv ordering information for General Practice

Ordering controls will be in place for general practices, to enable UKHSA to balance supply with demand. These controls work by allocating an amount of LAIV based on the number of registered eligible patients and are tailored to each practice.

UKHSA expects to be able to accommodate the following, however at this time, this information remains subject to change:

- each GP practice will initially be allocated sufficient LAIV to vaccinate at least 50% of their eligible patients (all 2 and 3 year olds, plus children in clinical risk groups from age 4 to <18 years) when ordering commences
- increases to these allocations may be made in response to demand and vaccine availability
- requests for extra vaccine will be considered on a case-by-case basis throughout the ordering period. Requests for additional vaccine should be sent to the helpdesk (helpdesk@immform.org.uk) and should be sent in good time before your order cut-off. Out of schedule deliveries will be by exception only

Multi-Branch Practices and LAIV allocations

Please note that GP practices or groups that operate over multiple sites but are part of the same organisation will have a joint allocation (as in previous years), even where each site has a unique ImmForm account. This means that it is possible for one site to potentially order all of the available vaccine for the group, unless there is local agreement on how the allocated volume is shared. UKHSA recommend that this agreement is in place before ordering opens to reduce the risk of supply interruption.

The information above allows practices to estimate the amount of vaccine they will be initially allocated, and how it should be split between all sites.

LAIv ordering information for school-age providers

A default weekly ordering cap of 450 packs (4,500 doses) per week will be in place for school provider accounts.

Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example where a provider covers a large area using a single account), a higher weekly cap should be requested via the UKHSA Flu Vaccine Operations team by emailing childfluvaccine@ukhsa.gov.uk. Requests should be made by Friday 25 August to ensure that accounts are set up correctly before vaccine ordering commences.

For one-off larger orders during the ordering period, requests should be made via helpdesk@immform.org.uk.

Inactivated flu vaccine ordering

The Cell Based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc) will be available to order, in a single dose pack, for:

- children in clinical risk groups aged from 6 months to less than 2 years old;
- children aged from 2 to <18 years old in clinical risk groups for whom LAIV is clinically contraindicated or otherwise unsuitable; and
- healthy children from 2 years old to those in school year 11, for whom LAIV is unsuitable (for example, due to objection to LAIV on the grounds of its porcine gelatine content)

Order controls will also be in place for this vaccine as follows:

- for GPs, there will be an initial cap of 10 doses/packs per week
- for school-age providers, there will be a cap of 450 doses/packs per week

For one-off larger orders of inactivated vaccines, requests should be made via helpdesk@immform.org.uk in good time before your order cut-off.

All influenza vaccines for the 2023/24 season

Information on all influenza vaccines that have been marketed in the UK for the 2023/24 season are available at [weblink 25](#).

ImmForm customers should report long-term changes to opening hours for deliveries

Customers should report long-term changes to the days and times when they can accept deliveries, such as routine training days and closures, by contacting Movianto UK Customer Care (MoviantoUK.NHSCC@movianto.com; 01234 587207). This should not be used to report short-term changes due to absence or holidays.

Customers are reminded to be prepared for any break in deliveries due to absences or holidays and to order accordingly. Please make sure you have sufficient room in your fridge for any additional vaccine you wish to stock. Deferred orders can also be placed in advance. Out of schedule deliveries cannot be arranged for failure to place orders in good time.

DTaP/IPV/Hib/HepB vaccine ordering

Supplies of DTaP/IPV/Hib/HepB vaccines Infanrix hexa® and Vaxelis® are available for the routine infant primary immunisations programme.

Orders for Infanrix hexa® remain unrestricted. Customers in England and Wales may order up to 20 packs of Vaxelis® per ImmForm account per week – this will vary for customers taking part in the Oxford Vaccine Group trial. Customers in Scotland should refer to their local ordering restrictions. Providers should not order more than 2 weeks' worth of stock to minimise wastage due to fridge failures. For assistance, please contact the ImmForm Helpdesk at helpdesk@immform.org.uk.

Change in schedule for the routine and eligible gay and bisexual men and other men who have sex with men (GBMSM) under age 25 years

From 1 September 2023, the HPV vaccine programme will change from a 2 dose to a 1 dose HPV vaccine schedule for eligible adolescents and gay and bisexual men and other men who have sex with men (GBMSM) aged less than 25 years; please see the UKHSA and NHSEI bipartite letter for details.

Eligible individuals who are known to be immunosuppressed at the time of vaccination and those who are living with HIV, including those on antiretroviral therapy, should continue to be offered a 3 dose schedule as per the 'HPV' and 'Immunisation of individuals with underlying medical conditions' Green Book chapters.

HPV vaccine will continue to be available to order through ImmForm in the usual way. However, please consider the schedule change when placing orders for HPV vaccine, and do not order more than 2 weeks' worth of stock to minimise wastage due holding excess stock, or fridge failures.

Update to Bexsero Patient Information Leaflet

Every pack of Bexsero (Meningitis B vaccine; 10 doses) issued via ImmForm in Great Britain, is supplied with a pad of 10 Patient Information Leaflets (PILs), as well as there being a single PIL inside each Bexsero pack. Since September 2020, an updated version of the PIL pad has been distributed with Bexsero orders. Please dispose of the single PIL from inside the pack and issue the updated PIL.

Registering for a new or updating your existing ImmForm vaccine ordering account

When you register for or update an existing ImmForm account, UK Health Security Agency as a wholesaler of vaccines need to verify the requesting customer.

Please ensure you have your professional regulatory body registration number or Wholesaler Dealer Licence and an organisation code which can be verified when requesting updates or requesting a new vaccine ordering account.

For more information please see the ImmForm Helpsheet – How to register at [weblink 4](#).

The EU Falsified Medicines Directive (FMD) and Delegated Regulation as applicable to UKHSA-supplied vaccines for the national immunisation programme

The EU Falsified Medicines Directive (see [weblink 26](#)) 2011/62/EU (FMD) and Delegated Regulation ((EU) 2016/161) (The Delegated Regulation) impose legal obligations on the EU medicines supply chain to prevent entry of falsified medicinal products into the supply chain. The Delegated Regulation was implemented in all EU Member States on 9 February 2019. Following the UK's departure from the EU, the Delegated Regulation ceased to apply in Great Britain from 31 December 2020, but continues to apply in Northern Ireland.

Information for customers in Northern Ireland

FMD-barcoded packs of routine immunisation programme vaccines that are centrally supplied by UKHSA continue to be supplied with active FMD serialisation, and should be decommissioned by end users in Northern Ireland. Customers in Northern Ireland who access centrally supplied vaccines are encouraged to review local guidance on implementation of the EU Falsified Medicines Directive.

MMR vaccine ordering

To rebalance central supplies of both MMR vaccines please consider ordering M-M-RvaxPRO® as your first choice, which is available without restriction.

Customers in England and Wales who require Priorix®, for example because you serve communities that do not accept vaccines containing porcine gelatine, may order up to 20 packs of Priorix® per ImmForm account per week. For assistance please contact the ImmForm Helpdesk at helpdesk@immform.org.uk. Customers in Scotland should refer to their local ordering restrictions.

Shingrix® vaccine ordering information



Current programme

Zostavax® for the previously eligible cohort will continue to be available until stocks deplete, after which time Shingrix® will be available. Ordering controls for Zostavax® will be advised on ImmForm news and the ImmForm ordering page.

New programme

Shingrix® for the new programme will be available to order from early August. Ordering controls for Shingrix® will be in place to manage initial demand and will be eased once stabilised. To minimise wastage due to fridge failures, ImmForm customers should order no more than 2 weeks' worth of stock.

For assistance please contact the ImmForm Helpdesk at helpdesk@immform.org.uk.

Non routine vaccination supply

HEPATITIS A VACCINE

Adult

- **GSK:** supply of Havrix Adult PFS singles and packs of 10 are currently available
- **Sanofi Pasteur:** Avaxim PFS singles and packs of 10 are currently available
- **MSD:** VAQTA Adult is available

Paediatric

- **GSK:** supply of Havrix Paediatric singles and packs of 10 are currently available
- **MSD:** VAQTA Paediatric is available
- **Sanofi Pasteur:** Avaxim Junior singles are currently available

HEPATITIS B VACCINE

Adult

- **GSK:** Engerix B PFS singles and packs of 10 are currently available
- **GSK:** supply of Fendrix is currently available
- **MSD:** HBVAXPRO 10 micrograms is available
- **MSD:** HBVAXPRO 40 micrograms is available
- **Valneva:** PreHevbri is available

Paediatric

- **GSK:** supply of Engerix B Paediatric singles is currently available
- **MSD:** HBVAXPRO 5 micrograms is available

COMBINED HEPATITIS A AND B VACCINE

- **GSK:** Twinrix Adult singles and packs of 10 are available
- **GSK:** Twinrix Paediatric is currently available
- **GSK:** Ambirix is available

COMBINED HEPATITIS A AND TYPHOID VACCINE

- **Sanofi Pasteur:** Viatim is now a discontinued product and no longer available for sale

TYPHOID VACCINE

- **Sanofi Pasteur:** Typhim singles and packs of 10 are available
- **Patientric:** Vivotif is available

Rabies vaccine

- **Valneva:** Rabipur is available. Due to high demand, orders are capped to maximum of 12 doses per order, per week (restrictions are anticipated to remain in place until the beginning of August)
- **Sanofi Pasteur:** Rabies BP is now a discontinued product and no longer available for sale

Pneumococcal polysaccharide vaccine (PPV)

- **MSD:** supply of Pneumovax 23 (PPV23) PFS is available

Pneumococcal polysaccharide conjugate vaccine (PCV)

- **Pfizer:** Prevenar 13 is currently available.

Varicella zoster vaccine

- **GSK:** VARILRIX is currently available
- **MSD:** VARIVAX is available
- **MSD:** ZOSTAVAX is now a discontinued product

Diphtheria, tetanus, pertussis (inactivated) vaccine

- **Sanofi Pasteur:** Revaxis is available

Diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated) vaccine

- **GSK:** supply of Boostrix-IPV is currently available
- **Sanofi Pasteur:** Repevax is currently available

MMR

- **MSD:** MMR Vaxpro is currently available
- **GSK:** Priorix is currently available

Meningitis ACWY vaccine

- **GSK:** Menveo is currently out of stock – expected recovery in October
- **Pfizer:** Nimenrix is currently available
- **Sanofi Pasteur:** MenQuadfi is available

Yellow fever

- **Sanofi Pasteur:** Stamaril is available

Human papillomavirus vaccine

- **MSD:** GARDASIL has been discontinued
(Please refer to ImmForm for NIP supply status)
- **MSD:** Gardasil 9 is currently available
- **GSK:** Cervarix has been discontinued

Cholera vaccine

- **Valneva:** Dukoral is available
- **Patientric:** Vaxchora is available

Japanese encephalitis vaccine

- **Valneva:** Ixiaro is available

Meningococcal group b vaccine

- **GSK:** Bexsero is currently available

Diphtheria, tetanus, pertussis, hib vaccine and poliomyelitis

- **GSK:** Infanrix IPV+Hib is currently available

Hib + meningococcal group c combined vaccine

- **GSK:** Menitorix is currently available

Live attenuated rotavirus vaccine

- **GSK:** Rotarix is currently available

Herpes zoster vaccine

- **GSK:** Shingrix is currently available

Weblinks

Weblink 1 <https://www.gov.uk/government/publications/shingles-herpes-zoster-the-green-book-chapter-28a>

Weblink 2 <https://www.medicines.org.uk/emc/product/12054/smpc>

Weblink 3 <https://portal.immform.phe.gov.uk/Logon.aspx>

Weblink 4 <https://www.gov.uk/government/publications/how-to-register-immform-helpsheet-8>

Weblink 5 <http://www.medicines.org.uk/emc/product/6101/pil>

Weblink 6 <https://www.medicines.org.uk/emc/product/12054/pil>

Weblink 7 <https://www.gov.uk/government/collections/immunisation-patient-group-direction-pgd>

Weblink 8 <https://www.gov.uk/government/publications/shingles-vaccination-guidance-for-healthcare-professionals>

Weblink 9 <https://www.gov.uk/government/collections/shingles-vaccination-programme>

Weblink 10 <https://www.healthpublications.gov.uk/Home.html>

Weblink 11 <https://www.gov.uk/government/publications/consent-the-green-book-chapter-2>

Weblink 12 www.mhra.gov.uk/yellowcard

Weblink 13 <https://www.healthpublications.gov.uk/ViewProduct.html?sp=Sshingleschecklist>

Weblink 14 <https://www.gov.uk/government/collections/vaccine-uptake#shingles-vaccine-uptake>

Weblink 15 <https://www.gov.uk/government/collections/shingles-vaccination-programme>

Weblink 16 <https://www.healthpublications.gov.uk/ViewProduct.html?sp=Sshinglesfullprogrammeposter>

Weblink 17 <https://www.gov.uk/government/publications/shingles-vaccination-eligibility-poster>

Weblink 18 <https://www.healthpublications.gov.uk/ViewProduct.html?sp=Sshinglesposteroosterquickguide>

Weblink 19 <https://www.healthpublications.gov.uk/ViewProduct.html?sp=Sshinglesleaflet>

Weblink 20 <https://www.healthpublications.gov.uk/ViewProduct.html?sp=Sshinglespostcard-3665>

Weblink 21 <https://www.healthpublications.gov.uk/ViewProduct.html?sp=Sshinglesrecordcard>

Weblinks

- Weblink 22 <https://www.healthpublications.gov.uk/ViewProduct.html?sp=Sshinglessticker>
- Weblink 23 <https://www.healthpublications.gov.uk/ViewArticle.html?sp=Sshingleswebandsocialmediabanners>
- Weblink 24 <https://portal.immform.phe.gov.uk/VaccineSupply/VaccineSupply/Home/Vaccine-Supply-Home.aspx>
- Weblink 25 <https://www.gov.uk/government/publications/influenza-vaccines-marketed-in-the-uk>
- Weblink 26 https://health.ec.europa.eu/system/files/2016-11/dir_2011_62_en_0.pdf